BHVN vs NRXP
BHVN: Biohaven is a biopharmaceutical firm developing a diverse pipeline of innovative therapies for complex diseases in neuroscience, immunology, obesity, and oncology. NRXP: A clinical-stage biopharmaceutical company developing NMDA-modulating neuroplasticity drugs for severe CNS disorders while operating an interventional psychiatric clinic network.
Side-by-side fundamentals
| Metric | BHVN | NRXP | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $11.81 | $2.62 | |
| Market cap | $1.8B | $113M | |
| Net margin FY2025, SEC XBRL | n/a | -2336.5% | |
| Operating margin FY2025, SEC XBRL | n/a | -1324.4% | |
| ROE FY2025, SEC XBRL | -1418.8% | n/a | |
| ROA FY2025, SEC XBRL | -163.7% | -220.9% | BHVN higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.53 | 1.07 | |
| 1-year return as of 2026-10-20 close | -32.7% | -20.8% | NRXP higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.